FDA Breakthrough Devices Program

The program is designed to expedite development, assessment and review of devices that offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions, where one of four additional criteria is also met. The mechanism is intensified FDA engagement and process flexibility — not a lower evidence standard. Safety and effectiveness expectations are unchanged; the program adapts the pathway to the realities of novel technologies.

A device must meet BOTH a primary criterion AND at least ONE secondary criterion:

Primary criterion

• Provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.

Secondary criteria (any one)

1. Represents Breakthrough technology.
2. No approved or cleared alternatives exist.
3. Offers significant advantages over existing approved or cleared alternatives (reducing morbidity/mortality, addressing serious unmet need, improving patient experience).
4. Device availability is in the best interest of patients.

1. Sponsor submits a Q-Sub Designation Request describing intended use, target population, the unmet need, the technology, and the rationale against eligibility criteria.
2. FDA target turnaround: 60 days for a designation decision.
3. If granted, the device is Breakthrough-designated; if denied, sponsor receives written rationale and may resubmit with additional information.
4. Designation can be granted at any point in device development — earlier is better for engagement value.

• Interactive and timely communication with FDA, including Sprint Discussions on focused topics.
• Data Development Plan — sponsor and FDA agree the evidence strategy for premarket and post-market, with explicit accommodations such as priority review, more flexible clinical study design and increased acceptability of real-world evidence.
• Senior management engagement on review issues.
• Priority review across all subsequent submissions (Pre-Subs, IDE, marketing).
• Recognition in CMS coverage pathways — TCET program prioritises Breakthrough-designated devices for coordinated coverage and reimbursement assessment.
• Public listing on FDA's Breakthrough Devices Program webpage (after marketing authorisation, by sponsor consent).

• Safety and effectiveness standard — unchanged.
• Substantial equivalence threshold for 510(k) — unchanged.
• User fees — designation alone does not waive MDUFA fees.
• Clinical evidence requirement — Breakthrough devices still require evidence appropriate to the regulatory pathway and risk.

The Data Development Plan is the central artefact. It documents the agreed approach to:

• Pivotal clinical study design — sample size, endpoints, comparator, statistical analysis plan.
• Acceptance of historical controls, external controls or real-world data where conventional comparators are not feasible.
• Surrogate endpoints with post-market commitments.
• Post-market evidence-generation commitments — real-world performance monitoring, registries, post-approval studies.
• Manufacturing and quality readiness milestones aligned to the clinical timeline.

The Data Development Plan typically commits the sponsor to substantive post-market evidence generation. The FDA may approve based on a relatively earlier evidence package on the strength of the Breakthrough framework, with post-market obligations rebalancing the overall benefit-risk picture. Sponsors must resource post-market commitments seriously — failure to meet post-approval study obligations is treated as a compliance issue.

Breakthrough designation is increasingly recognised by CMS. The TCET pathway (Transitional Coverage for Emerging Technologies) prioritises a subset of Breakthrough-designated devices for coordinated NCD review aligned to FDA marketing authorisation. Private payers also reference Breakthrough designation in coverage policy development, though acceptance varies.

FDA publishes annual Breakthrough Devices Program metrics. As of recent reporting, designation grant rate has been roughly 60-70% of well-prepared requests; cumulative marketing authorisations under the program have grown year over year. Cardiology, oncology, neurology and digital therapeutics have featured prominently.